Sponsored Links
Lymphoma Information Network » Lymphoma Info » Non-Hodgkin's Lymphoma Incidence

Non-Hodgkin's Lymphoma Incidence

lymphoma tumor cells
Lymphoma tumor cells (NCI)

In epidemiology, "incidence rate" is a measure of how many people within a given population will develop a disease or other condition during a specified period of time. It is, essentially, a measurement of risk.

The National Cancer Institute estimates that 65,980 new cases of Non-Hodgkin's Lymphoma will be diagnosed in 2009. This represents 89% of all lymphomas, and 4% of all cancers diagnosed. It is the seventh most common cancer in the United States.

According to the Leukemia and Lymphoma Society:

  • The chance of developing Non-Hodgkin's Lymphoma during your lifetime is 1 in 50, or 2%. However, this percentage increases if you have one or more risk factors for the disease.
  • NHL is more prevalent in males than females–55% of lymphoma diagnoses are for male patients
  • Of those diagnosed with the disease, 95% are adults and 5% are children
  • It is more prevalent in patients over the age of 60
  • The average age at diagnosis is 65
  • Due to aging of the "baby boom" population, the incidence of NHL is expected to rise in the coming years

Lymphoma is a well-researched subject and many statistics are published annually. For the most up-to-date and complete statistical information on lymphoma, please see the resources listed at the bottom of the page.

Sponsored Links

Cancer Support Groups

SupportGroups.com aims to build awareness and provide support for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma. If you are a friend or parent of a person that has been diagnosed with Lymphoma, or you have been diagnosed with Lymphoma, you are not alone. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Dive Deeper

Lymphoma statistics resources

Related Articles

disclaimer

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
Featured Treatment
searching for treatment

Featured Treatment: Zevalin®

Zevalin® (Ibritumomab tiuxetan) is a form of radioimmunotherapy (a radiolabeled monoclonal antibody) for treatment of patients with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL). "Refractory" refers to a disease that does not respond to treatment.

Zevalin is the first radioummunotherapy treatment to be FDA-approved as a first-line therapy for lymphoma. Read more...

Sponsored Links
User login
Cancer Support Groups

Cancer Support Groups

support groups

SupportGroups.com aims to build awareness and provide support for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma. If you are a friend or parent of a person that has been diagnosed with Lymphoma, or you have been diagnosed with Lymphoma, you are not alone. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Poll
What is most important to you in an Online Support Group?:
Latest Blog Entries

Did You Know?
Since the early 1970s, incidence rates for non-Hodgkin’s lymphoma have nearly doubled. Incidence rates for Hodgkin’s disease have declined about 60%. Better means of diagnosis has also increased the number as doctors better understand cancer of lymphocytes verses other diseases.
lymphomas